Aspirin Low Dose Chewable
NDC Package 67046-165-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Aspirin Low Dose Chewable is allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels  The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables) Limitations of Use Allopurinol Tablets are not recommended for the treatment of asymptomatic hyperuricemia. Marketed by Contract Pharmacy Services-pa, this product is identified by NDC 67046-165 and is authorized under FDA application part343.

Identification & Billing

NDC Package Code
67046-165-30
Package Description
30 TABLET, CHEWABLE in 1 BLISTER PACK
Product Code
67046-165
11-Digit Billing Format
67046016530
RxNorm Crosswalk
RxCUI: 197320 - allopurinol 300 MG Oral Tablet

Clinical Specifications

Proprietary Name
Aspirin Low Dose Chewable
Dosage Form
-
Usage Information
Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels  The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables) Limitations of Use Allopurinol Tablets are not recommended for the treatment of asymptomatic hyperuricemia.

Regulatory & Marketing

Labeler Name
Contract Pharmacy Services-pa
FDA Application #
part343
Marketing Category
OTC MONOGRAPH FINAL - A product marketed pursuant to a final Over-the-Counter (OTC) Drug Monograph.
Start Marketing Date
08-09-2010
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67046-165-30 identifies a specific commercial package of 30 tablet, chewable in 1 blister pack of Aspirin Low Dose Chewable, labeled by Contract Pharmacy Services-pa. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Contract Pharmacy Services-pa on August 09, 2010. The current certification is valid through December 31, 2017.

How is this Contract Pharmacy Services-pa product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67046016530. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
67046-165-30
11-Digit CMS (5-4-2)
67046-0165-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.